Patients with colorectal cancer are characterized by increased concentration of fecal Hb-Hp complex, myeloperoxidase, and secretory IgA

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 6, 2011, Pages 561-566

  Chalkias, Athanasios ^a,b   Nikotian, George ^c   Koutsovasilis, Anastasios ^b   Bramis, John ^a   Manouras, Andreas ^a   Mystrioti, Dimitra ^b   Katergiannakis, Vaggelogiannis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c Department of Microbiology   (Greece)

Author keywords

colorectal cancer; Hb Hp complex; myeloperoxidase; screening; secretory IgA

Indexed keywords

CD163 ANTIGEN; IMMUNOGLOBULIN A; MYELOPEROXIDASE;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; COLORECTAL NEOPLASMS; FECES; FEMALE; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN A, SECRETORY; MALE; MASS SCREENING; MIDDLE AGED; PEROXIDASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 81855163403     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181f9457e     Document Type: Article

References (53)

1. Jemal AJ, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Yang GY, Taboada S, Liao J. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. Methods Mol Biol. 2009;511:193-233.
3. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets. 2008;9:375-380.
4. Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res. 2006;130:1-38.
5. Westbrook AM, Wei B, Braun J, et al. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res. 2009;69:4827-4834.
6. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7-G17.
7. Bond JH. Screening guidelines for colorectal cancer. Am J Med. 1999;106:7S-10S.
8. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-1477.
9. Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-437.
10. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42: 1589-1600.
11. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 1994;305:253-264.
12. Stone WL, Papas AM. Tocopherols and the etiology of colon cancer. J Natl Cancer Inst. 1997;89:1006-1014.
13. Frode TS, Medeiros YS. Myeloperoxidase and adenosine deaminase levels in pleural fluid leakage induced by carrageenan in the mouse model of pleurisy. Mediators Inflamm. 2001;10:223-227.
14. Rainis T, Maor I, Lanir A, et al. Enhanced oxidative stress and leucocyte activation in neoplastic tissues of the colon. Dig Dis Sci. 2007;52:526-530.
15. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3-21.
16. Nauseef WM, Olsson I, Arnljots K. Biosynthesis and processing of myeloperoxidase: a marker for myeloid cell differentiation. Eur J Haematol. 1988;40:97-110.
17. Otamiri T, Sjodahl R. Increased lipid peroxidation in malignant tissues of patients with colorectal cancer. Cancer. 1989;64:422-425.
18. Parkin DM, Pisani P, Munoz N, et al. Infections and Human Cancer. Cold Spring Harbor, (NY): Cold Spring Harbor Laboratory Press; 1999.
19. Royle L, Roos A, Harvey DJ, et al. Secretory IgA N- and Oglycans provide a link between the innate and adaptive immune systems. J Biol Chem. 2003;278:20140-20153.
20. Brooks JJ, Ernst CS. Immunoreactive secretory component of IgA in human tissues and tumors. Am J Clin Pathol. 1984;82:660-665.
21. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet. 2002;359:403-404.
22. Gulumian M. The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Mol Cell Biochem. 1999;196:69-77.
23. Kato M, Shinohara H, Goto S, et al. Clinical experience of EET therapy for 75 advanced cancer patients. Anticancer Res. 1998; 18:3941-3949.
24. Tasaki K, Yoshida Y, Maeda M, et al. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-19, which activate type 1 helper T cells. Cancer Gene Ther. 2000;7:247-254.
25. Sieg A, Thoms C, Lüthgens K, et al. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces. Int J Colorectal Dis. 1999;14:267-271.
26. Meguro T. Measurement of fecal hemoglobin-haptoglobin complex as a new diagnostic tool of lower gastrointestinal tract diseases. Hokkaido Igaku Zasshi. 1994;69:995-1009.
27. Roncucci L, Mora E, Mariani F, et al. Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:2291-2297.
28. Keshavarzian A, Zapeda D, List T, et al. High levels of reactive oxygen metabolites in colon cancer tissue: analysis by chemiluminescence probe. Nutr Cancer. 1992;17:243-249.
29. Bruce WR, Giacca A, Medline A. Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:1271-1279.
30. Sansbury LB, Bergen AW, Wanke KL, et al. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15: 494-501.
31. Gunter MJ, Canzian F, Landi S, et al. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1126-1131.
32. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2003;307:1920-1925.
33. Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol. 2003;16:347-358.
34. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11-22.
35. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001;85:473-783.
36. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 2002;8:10-15.
37. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
38. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
39. Landi S, Moreno V, Gioia-Patricola L, et al. Association of common polymorphisms in inflammatory genes interleukin IL6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003;63:3560-3566.
40. Macarthur M, Sharp L, Hold GL, et al. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev. 2005;14:1613-1618.
41. Kettunen HL, Kettunen AS, Rautonen NE. Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res. 2003;63:5136-5142.
42. Koretz K, Schlag P, Quentmeier A, et al. Evaluation of the secretory component as a prognostic variable in colorectal carcinoma. Int J Cancer. 1994;57:365-370.
43. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol. 2009;104:739-750.
44. Nakajima M, Saito H, Soma Y, et al. Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study. Br J Cancer. 2003;89: 23-28.
45. Lee KJ, Inoue M, Otani T, et al. Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev. 2007;31: 3-11.
46. Zappa M, Castiglione G, Grazzini G, et al. Effect of faecal occult blood testing on colorectal mortality: results of a population-based case-control study in the district of Florence, Italy. Int J Cancer. 1997;73:208-210.
47. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155-159.
48. Parra-Blanco A, Gimeno-García AZ, Quintero E, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol. 2010 [Epub ahead of print].
49. Nishikawa T, Maemura K, Hirata I, et al. A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/ restriction fragment length polymorphism analysis. Clin Chim Acta. 2002;318:107-112.
50. Rengucci C, Maiolo P, Saragoni L, et al. Multiple detection of genetic alterations in tumors and stool. Clin Cancer Res. 2001; 7:590-593.
51. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119: 1219-1227.
52. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:858-865.
53. Tagore KS, Lawson MJ, Yucaitis JA, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer. 2003;3: 47-53.